95 -4 (78) 2025 - Turdiyev T.U. - CAUSES, SYMPTOMS, TREATMENT METHODS AND PROPHYLAXIS OF HEPATITIS C

CAUSES, SYMPTOMS, TREATMENT METHODS AND PROPHYLAXIS OF HEPATITIS C

Turdiyev T.U. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Hepatitis C is a chronic liver infection caused mainly by the hepatitis C virus (HCV). Over the past decade, there have been significant advances in the treatment of hepatitis C, especially with the development and use of new-generation direct-acting antiviral (DAA) drugs, which have significantly improved the effectiveness of treatment. DAA drugs are characterized by high efficacy, rapid results and few side effects in the treatment of hepatitis C. In this regard, they play an important role in preventing the development of liver cirrhosis, liver failure or other complications associated with hepatitis C. For patients diagnosed in the early stages, antiviral treatment is beneficial in all respects, allowing for complete eradication of the virus. However, there are still challenges in the diagnosis and treatment of hepatitis C, including resource constraints, a global epidemic and the high cost of new-generation drugs. At the same time, new approaches and methods are being sought in the clinical management and prevention of hepatitis C.

Keywords: hepatitis C, diagnostics, liver failure, chronic hepatitis, therapy, new treatment methods, viral infection, prevention of hepatitis C epidemic.

First page

558

Last page

561

For citation:Turdiyev T.U. - CAUSES, SYMPTOMS, TREATMENT METHODS AND PROPHYLAXIS OF HEPATITIS C//New Day in Medicine 4(78)2025 558-561 https://newdayworldmedicine.com/en/new_day_medicine/4-78-2025

List of References

  1. Afdhal, N., Reddy, K. R., Kwo, P. Y. (2017). The path to a cure: hepatitis C therapy and the emergence of direct-acting antivirals. Journal of Hepatology, 66(1), 1-10.
  2. Ferenci, P., & Bernstein, D. (2015). Hepatitis C treatment in the era of direct-acting antiviral agents. Journal of Clinical Hepatology, 29(3), 123-130.
  3. Anderson, K. M., et al. (2016). Impact of hepatitis C virus on the global population. Journal of Infectious Diseases, 213(4), 670-678.
  4. Charlton, M., Cihlar, T. (2019). Hepatitis C virus treatment and the role of direct-acting antivirals. Hepatology, 69(1), 229-240.
  5. EASL (European Association for the Study of the Liver). (2018). Hepatitis C: Current perspectives on treatment and diagnosis. EASL Clinical Practice Guidelines.
  6. Dore, G. J., & Cooke, G. S. (2017). Global epidemiology of hepatitis C virus infection: Clinical consequences and management. Current Opinion in Infectious Diseases, 30(6), 509-517.
  7. Borgia, S. M., et al. (2018). Hepatitis C treatment regimens: an update. Liver International, 38(7), 1150-1160.
  8. Martín-Carbonero, L., et al. (2015). Hepatitis C treatment in special populations: HIV-coinfected patients, patients with cirrhosis, and those with end-stage renal disease. Antiviral Therapy, 20(4), 363-378.
  9. Zeuzem, S., et al. (2020). Sofosbuvir and velpatasvir for patients with hepatitis C infection. The New England Journal of Medicine, 382(18), 1709-1719.
  10. McGowan, C. E., et al. (2019). Hepatitis C in 2019: Innovations in treatment and future directions. Gastroenterology, 157(6), 1493-1504
  11. D.B. Mirzakarimova, Ya.M. Yuldashev “Yuqumli kasalliklarning erta va differensial diagnostikasi” 2019 yil, 108 bet.
  12. M.D. Ahmedova, A.R. Obloqulov, S.N. Boboxo‘jaev “Yuqumli kasalliklarda hamshiralik ishi” 2008 yil, 85 bet.
  13. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirining 2024 yil 29 martdagi buyrug‘iga asosan tuzilgan O‘zbekiston Respublikasi Sog‘liqni Saqlash Vazirligi Respublika Ixtisoslashtirilgan Epidemiologiya, Mikrobiologiya, Yuqumli va Parazitar Kasalliklar Ilmiy-Amaliy Tibbiyot Markazining “O‘tkir virusli gepatit A va E” nozologiyasi bo‘yicha milliy klinik protokoli.
  14. Internet ma’lumotlari: https:/uz.wikipedia.org, https://www.who.int, https://kun.uz, https://ww.smclinic.ru, https://med24.uz, https://mymedic.uz

    file

    download